{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:33Z","timestamp":1740144033894,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"publisher","award":["CDA"],"award-info":[{"award-number":["CDA"]}],"id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40257-019-00425-x","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T12:54:42Z","timestamp":1548939282000},"page":"311-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trends in Utilization and Expenditure for Onychomycosis Treatments in the United States in 2013\u20132016"],"prefix":"10.1007","volume":"20","author":[{"given":"Partik","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"issue":"2 Suppl 1","key":"425_CR1","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.12788\/j.sder.0014","volume":"32","author":"RK Scher","year":"2013","unstructured":"Scher RK, Rich P, Pariser D, Elewski B. The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg. 2013;32(2 Suppl 1):S2\u20134.","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"425_CR2","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.jaad.2015.11.053","volume":"75","author":"JP Lagrew","year":"2016","unstructured":"Lagrew JP. A financial perspective on the topical treatment of onychomycosis. J Am Acad Dermatol. 2016;75(1):e37.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"425_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/1203475417733461","volume":"22","author":"AK Gupta","year":"2018","unstructured":"Gupta AK, Versteeg SG, Shear NH. Confirmatory testing prior to initiating onychomycosis therapy is cost-effective. J Cutan Med Surg. 2018;22(2):129\u201341.","journal-title":"J Cutan Med Surg."},{"issue":"3","key":"425_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamadermatol.2015.4190","volume":"152","author":"A Mikailov","year":"2016","unstructured":"Mikailov A, Cohen J, Joyce C, Mostaghimi A. Cost-effectiveness of confirmatory testing before treatment of onychomycosis. JAMA Dermatol. 2016;152(3):276\u201381.","journal-title":"JAMA Dermatol."},{"key":"425_CR5","unstructured":"CPI Inflation Calculator. 2018 2018 [cited 11 Jul 2018]. \n                    https:\/\/www.bls.gov\/data\/inflation_calculator.htm\n                    \n                  . Accessed 17 June 2018."},{"issue":"7","key":"425_CR6","first-page":"815","volume":"13","author":"AK Gupta","year":"2014","unstructured":"Gupta AK, Elewski BE, Sugarman JL, Ieda C, Kawabata H, Kang R, et al. The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials. J Drugs Dermatol. 2014;13(7):815\u201320.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"425_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/09546634.2017.1329510","volume":"29","author":"AK Gupta","year":"2018","unstructured":"Gupta AK, Hall S, Zane LT, Lipner SR, Rich P. Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies. J Dermatol Treat. 2018;29(1):44\u20138.","journal-title":"J Dermatol Treat."},{"key":"425_CR8","doi-asserted-by":"crossref","unstructured":"Kreijkamp-Kaspers S, Hawke K, Guo L, Kerin G, Bell-Syer SE, Magin P, et al. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017;7:CD010031.","DOI":"10.1002\/14651858.CD010031.pub2"},{"issue":"12","key":"425_CR9","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/jamadermatol.2017.4483","volume":"153","author":"D Patel","year":"2017","unstructured":"Patel D, Castelo-Soccio LA, Rubin AI, Streicher JL. Laboratory monitoring during systemic terbinafine therapy for pediatric onychomycosis. JAMA Dermatol. 2017;153(12):1326\u20137.","journal-title":"JAMA Dermatol."},{"issue":"5","key":"425_CR10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1001\/jamadermatol.2018.0094","volume":"154","author":"DG Li","year":"2018","unstructured":"Li DG, Mostaghimi A. Utility of baseline transaminase monitoring during systemic terbinafine therapy for pediatric onychomycosis. JAMA Dermatol. 2018;154(5):626\u20137.","journal-title":"JAMA Dermatol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-019-00425-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00425-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00425-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T19:24:41Z","timestamp":1580412281000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-019-00425-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["425"],"URL":"https:\/\/doi.org\/10.1007\/s40257-019-00425-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"type":"print","value":"1175-0561"},{"type":"electronic","value":"1179-1888"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"assertion":[{"value":"31 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This publication was made possible with support from the Dermatology Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PS and JS have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}